Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Gilead Sciences Inc (GILD)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 100,276,056
  • Shares Outstanding, K 1,300,260
  • Annual Sales, $ 26,107 M
  • Annual Income, $ 4,628 M
  • 36-Month Beta 1.12
  • Price/Sales 3.84
  • Price/Cash Flow 8.02
  • Price/Book 4.87

Price Performance

See More
Period Period Low Period High Performance
1-Month
68.60 +12.32%
on 06/27/18
78.17 -1.43%
on 07/12/18
+6.11 (+8.61%)
since 06/19/18
3-Month
64.27 +19.88%
on 05/03/18
78.17 -1.43%
on 07/12/18
+2.61 (+3.51%)
since 04/19/18
52-Week
64.27 +19.88%
on 05/03/18
89.54 -13.95%
on 01/29/18
+4.33 (+5.95%)
since 07/19/17

Most Recent Stories

More News
5 Biotech Stocks Well Poised to Beat Q2 Earnings Estimates

Biotech industry experiences a turnaround in June. Here are five stocks which are expected to beat expectation in Q2.

ABUS : 11.40 (+0.88%)
KERX : 4.49 (+0.45%)
GILD : 77.05 (-0.09%)
ACOR : 29.15 (+1.57%)
ICPT : 95.73 (+0.05%)
J&J's Darunavir-Based Single-Tablet HIV Regimen Gets FDA Nod

The FDA approves Johnson and Johnson's (JNJ) darunavir-based single-tablet regimen, Symtuza, for the treatment of type 1 HIV-1 in treatment-naive and certain virologically suppressed adults.

ILMN : 309.10 (+0.59%)
JNJ : 125.94 (-1.46%)
GILD : 77.05 (-0.09%)
GSK : 40.69 (-0.68%)
Gilead Sciences to Release Second Quarter 2018 Financial Results on Wednesday, July 25, 2018

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its second quarter 2018 financial results will be released on Wednesday, July 25, after the market closes. At 5:00 p.m. Eastern Time,...

GILD : 77.05 (-0.09%)
Gilead Sciences (GILD) Crosses Pivot Point Support at $76.18

Shares of Gilead Sciences (NASDAQ:GILD) have bearishly opened below the pivot of $76.81 today and have reached the first support level of $76.18. Investors may be interested in a cross of the next downside...

GILD : 77.05 (-0.09%)
The Zacks Analyst Blog Highlights: Mastercard, Gilead, Goldman Sachs, PepsiCo and Aetna

The Zacks Analyst Blog Highlights: Mastercard, Gilead, Goldman Sachs, PepsiCo and Aetna

AET : 190.04 (-0.67%)
MA : 206.06 (-1.10%)
PEP : 115.77 (+0.82%)
GILD : 77.05 (-0.09%)
GS : 229.63 (-0.70%)
Is Invesco Zacks Multi-Asset Income ETF (CVY) a Hot ETF Right Now?

Smart Beta ETF report for CVY

C : 68.99 (-1.23%)
CVY : 22.38 (+0.58%)
DRI : 111.81 (-0.30%)
GILD : 77.05 (-0.09%)
Michael Amoroso to Join Kite as Senior Vice President and Head of Worldwide Commercial, Cell Therapy

Kite, a Gilead Company (NASDAQ: GILD), announced today that Michael Amoroso will join the company as Senior Vice President and Head of Worldwide Commercial, Cell Therapy. In this position,...

GILD : 77.05 (-0.09%)
Gilead Sciences Rises 2.09% on Heavy Volume: Watch For Potential Pullback

Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $75.21 to a high of $77.07. Yesterday, the shares gained 2.1%, which took the trading range above the 3-day high of...

GILD : 77.05 (-0.09%)
Top Research Reports for Mastercard, Gilead & Goldman Sachs

Top Research Reports for Mastercard, Gilead & Goldman Sachs

AET : 190.04 (-0.67%)
MA : 206.06 (-1.10%)
PEP : 115.77 (+0.82%)
GILD : 77.05 (-0.09%)
GS : 229.63 (-0.70%)
EOG : 122.39 (-0.96%)
Today's Research Reports on Trending Tickers: Gilead Sciences and bluebird bio

NEW YORK, NY / ACCESSWIRE / July 6, 2018 / U.S. markets rose Thursday on the strength of the technology sector, yet investors appear to be apprehensive as the U.S. prepare to place tariffs on Chinese...

GILD : 77.05 (-0.09%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators mostly agree with the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade GILD with:

Business Summary

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The Company strive to transform and simplify care for people with life-threatening illnesses around the world. Gilead's portfolio of products...

See More

Key Turning Points

2nd Resistance Point 78.60
1st Resistance Point 77.83
Last Price 77.05
1st Support Level 76.18
2nd Support Level 75.30

See More

52-Week High 89.54
Fibonacci 61.8% 79.89
Last Price 77.05
Fibonacci 50% 76.90
Fibonacci 38.2% 73.92
52-Week Low 64.27

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar